SlideShare une entreprise Scribd logo
1  sur  40
Télécharger pour lire hors ligne
3rd$Annual$Execu.ve$Global$
Clinical$Trials$
Mitchell(Katz,(Ph.D.(
Execu3ve(Director,(Medical(Research(Opera3ons(
Purdue(Pharma(L.P.(
September(2012(
2(
Pharma’s$Largest$Layoffs$in$2012$
3(
CRO$Consolida.on$
!  INC(
"  Kendle(
!  Theorem(
"  Omnicare(
"  IBAH(
!  Pharmanet/i3(
"  Inven3ve(Health(
!  Private(Equity(
"  PPD(
"  RPS(
"  PRA(
4(
Outsourcing$Buzz$Words$
!  Partnerships(
!  Alliances(
!  Preferred(Models(
!  Hybrid(Models(
!  Func3onal(Models(
!  Transac3onal(Models(
!  Offshoring(
!  “Strategic(Rela3onships”(
5(
Johnson$&$Johnson$and$ICON$
#1(–(Failure(to(ensure(proper(monitoring(of(the(clinical(
inves3ga3ons([21(CFR(312.50(and(312.56(a)(
#2(–(Failure(to(ensure(that(an(inves3ga3on(was(conducted(in(
accordance(with(the(general(inves.ga.onal$plan$and(
protocols(as(specified(in(the(IND([21(CFR(312.50](
#3(–(Failure(to(secure(inves.gator$compliance$with(the(
inves3ga3onal(plan(and(applicable(FDA(regula3ons([21(CFR(
312.56(b)](
#4(–(Failure(to(ensure(that(only(inves3gators(who(were(
qualified(by(training(and(experience(were(selected(as(
appropriate(experts(to(inves3gate(a(drug([21(CFR(212.53(a)](
6(
7(
It’s$All$About$.$.$.$
(
(
QUALITY$
8(
Avoca$Quality$Consor.um$
(
Pharma(and(Biotech(members((to(date):(
!  Alexion(Pharmaceu3cals,(Amgen,(Astellas(Pharma,(AstraZeneca,(Biogen(
Idec,(BristoldMyers(Squibb,(Cerexa,(Cubist(Pharmaceu3cals,(Daiichi(
Sankyo,(Eli(Lilly(and(Company,(GlaxoSmithKline,(Grünenthal,(ImClone(
Systems,(Janssen(Research(&(Development,(Otsuka,(Pfizer,(Purdue,(and(
Roche(
CRO(members((to(date):(
!  Chiltern(Interna3onal,(Covance,(INC(Research,(ICON,(Harrison(Clinical(
Research,(PAREXEL(Interna3onal,(PharmaNet/i3,(PRA(Interna3onal,(
Quin3les,(Theorem(Clinical(Research,(and(RPS(
(
Corporate(Sponsors:(
Quality$Management$and$CRO$
Oversight$
10(
Agenda$
!  Overview:(Background(and(context(
!  Part$1:(Overall(percep3ons(and(the(
“disconnects”(between(sponsors(and(CROs(
around(issues(of(quality(
!  Part$2:(Root(causes(of(quality(issues(and(the(
issue(of(“micromanagement”(
!  Part$3:(Best(prac3ce(approaches(associated(
with(sa3sfac3on(
!  Open(discussion(
11(
Context$for$Research$on$Quality$and$
CRO$Oversight$
!  Increase(in(clinical(outsourcing(
!  Consolida3on(of(spend(with(few(clinical(service(providers(
!  Globaliza3on(of(clinical(trials:(increase(in(number(of(studies(in(lessdexperienced(developing(
regions(
!  Focus(on(efficiencies(and(cost(savings(
!  Increase(in(the(number(of(highdprofile(FDA(warning(lemers(
Focus(on(Avoca’s(2011(Industry(Survey:(percep3ons(from(sponsors(and(CROs(on(the(quality(of(
outsourced(trials(
Focus(of(Avoca’s(Quality(Consor3um:(proac3ve(quality(management(
The$focus$and$vision$of$the$Quality$Consor5um$are$to$accelerate$the$development$of$an$industry$
standard$and$best9prac5ce$approach$to$the$quality$management$of$outsourced$trials$through$the$
sharing$of$best$prac5ces$
12(
Methods$
!  Surveys(explored(respondents’(views(and(experiences(regarding:(
"  Sa3sfac3on(with(quality(of(work(delivered(by(clinical(service(providers(
"  Approaches(to(managing(quality(in(outsourced(clinical(trials,(including(
quality(metrics,(repor3ng(tools,(and(desktop(analy3cs(
"  Scope(and(u3lity(of(Quality(Agreements(
"  Other(tools(used(to(set(expecta3ons(for(quality(in(outsourced(clinical(
trials(
"  Quality(concerns(and(management(when(outsourcing(in(Emerging(
Markets(
"  Quality(considera3ons(in(selec3ng(CROs(
13(
2011$Industry$Survey$
!  104(sponsor(surveys(from(66(
companies(
"  73%(pharma,(
17%(biotech(
"  52%(“Top(20”(
"  44%(Opera3ons,(
40%(Outsourcing(
"  17%(execu3ves,(
58%(middle(management((
!  143(provider(surveys(from(88(
companies(
"  78%(CROs(
"  64%(“Top(20”(
"  38%(Opera3ons,(
31%(BD,(
22%(Management(
"  48%(execu3ves,(
39%(middle(management((
247(Surveys(
14(
Quality$Consor.um$Assessment$
!  428(sponsor(surveys(were(deployed(resul3ng(in(feedback(from(334(
individuals(
"  Overall(response(rate:(78%(
"  Completed(surveys/company:(10d46((note(that(there(was(no(associa3on(
between(company(size(and(number(of(respondents)(
"  Range(of(response(rates/company:(50%d100%(
!  298(CRO(surveys(were(deployed(resul3ng(in(feedback(from(207(individuals(
"  Overall(response(rate:(69%(
"  Completed(surveys/company:(4d59((note(that(there(was(no(associa3on(
between(company(size(and(number(of(respondents)(
"  Range(of(response(rates/company:(27%d100%(
Part$1:$$Framing$the$Quality$Issue$
Overall(percep3ons(and(the(
“disconnects”(between(sponsors(and(
CROs(around(issues(of(quality(
16(
Methods$
!  “Quality”(was(defined(as(“The$ability$to$effec.vely$and$efficiently$answer$
the$intended$ques.on$about$the$benefits$and$risks$of$a$medical$product$
or$procedure$while$assuring$pa.ent$safety$and$protec.on$of$human$
subjects”$
!  As(examples,(elements(of(a(quality(clinical(study(were(said(to(include,(but(
not(limited(to:(
"  Scien3fically(valid(and(ethically(sound(experimental(design(
"  Adequate(protec3on(of(subjects’(rights,(safety(and(welfare(
"  Qualified(personnel(
"  Adequate(monitoring(
"  Current,(complete,(and(accurate(data(
"  Accurate(presenta3on(and(interpreta3on(of(data(
17(
Industry$Survey$Sponsors:$Overall$
Sa.sfac.on$
18(
Consor.um$Sponsors:$Sa.sfac.on$
with$Quality$
19(
Consor.um$Sponsors:$Comparison$of$
CRO$Quality$to$Sponsor$Internal$
Teams$
20(
Sa.sfac.on$with$Quality$
21(
Industry$Survey:$Provider$Sa.sfac.on$
22(
Sponsors:$Sa.sfac.on$with$Quality$
Areas(with(rela3vely(high(sa3sfac3on(included:(
!  Compliance(with(SOPs(and(other(wrimen(procedures(
!  Data$quality$and$integrity$
!  Audit(plans(and(execu3on(
Areas(with(rela3vely(high(dissa3sfac3on(included:(
!  Oversight(of(third(party(vendors(
!  Governance(of(quality(
!  Communica3ons(surrounding(quality(
!  Availability(of(quality(personnel(for(projects(
!  Efficiency/.meliness$in$achieving$clean$data$
!  Adherence(to(monitoring(plan(
Part$2:$$Causes$of$Quality$Issues$
24(
Causes$of$Issues$with$Quality$
“CROs,$as$service$providers,$are$heavily$incented$to$
deliver$and$measure$quality$–$and$are$prepared$to$do$
so.$$Too$many$sponsors$are$not$prepared$to$do$their$
part$in$assuring$a$rela5onship$focused$on$quality.$$So$
CROs$are$forced$to$implement$one$model$for$sponsors$
ready$to$focus$on$quality,$and$another$for$the$many$
focused$on$ac5vi5es$and$unit9level$cost.”$
( ( (d(Quota3on(from(an(Industry(Survey(Provider(Respondent(
(
(
25(
Causes$of$Issues$with$Quality:$Sponsor$
Consor.um$Data$
26(
Industry$Survey:$Causes$of$Issues$with$
Quality$
27(
Quality$vs.$Costs$
28(
Causes$of$Issues$with$Quality$
#1:$Cost$Pressures$
“The$focus$on$price$has$driven$out$the$reality$of$adequate$
monitoring$and$proper$Quality$Control$processes$to$ensure$quality$
at$the$site$level…$Too$many$procurement$officers$are$making$
decisions$purely$on$cost$without$regards$to$quality$product.”$
“Price$pressures,$especially$discounts…have$caused$some$CROs$to$
cut$corners$and$send$work$to$low$cost$regions$without$adequately$
trained$staff.”$
“Price$reduc5ons$required$to$‘play$the$game’$in$the$preferred$
provider$selec5on$process$make$it$very$difficult$to$con5nue$to$
resource$adequately.$$Sponsors$say$they$will$streamline$processes$
going$forward$to$reduce$workload$but$hardly$ever$do.”$
29(
Causes$of$Issues$with$Quality$
#2:(Sponsors(DecisiondMaking(with(
Impacts(on(Quality((without(provider(
input)(
!  Oversight((level(of(monitoring)(
!  Protocol(design(
!  Inves3gators(&(regions(
!  Timelines(
!  Processes(
!  Thirddparty(vendors(
“It$is$difficult$to$ensure$quality$for$a$func5onal$provider$for$monitoring,$when$
the$protocol$design/site$selec5on$are$done$by$another$CRO/sponsor.”$
“There$is$a$percentage$of$work$that$we$perform$that$is$working$with$the$
sponsor$processes,$etc…in$these$circumstances,$quality,$5meliness,$training,$
governance$and$oversight$are$dictated$by$sponsor$requirements.”$
30(
Causes$of$Issues$with$Quality$
#3:$Sponsor$Failure$to$Proac.vely$Make$Decisions$or$
Communicate$with$Providers$about$Quality$Expecta.ons$
Industry(survey(data:(
!  Only(55%(of(sponsors(are(sa3sfied(with(their(companies’(iden3fica3on(of(process/
deliverables(for(which(quality(expecta3ons(of(CROs(need(to(be(set.(
!  Only(58%(feel(that(their(companies(effec3vely(communicate(quality(expecta3ons(
to(CROs(
!  Strong(associa3on(between(“proac3ve”(management(of(quality(and(ability(to(
forego(micromanagement.(
Part$3:$$Results$
What(can(be(done(to(enhance(quality(while(
reducing(micromanagement?(
What$quality$prac.ces$are$associated$with$
enhanced$sa.sfac.on?$
32(
Industry$Survey$Sponsors:$Quality$
Metrics$
33(
Consor.um$Survey:$Quality$Metrics$
34(
Quality$Agreements$
35(
Industry$Survey$Sponsors:$Quality$
Agreements$
36(
Industry$Survey$Sponsors:$Quality$
Agreements$
37(
Other$Prac.ces$Impac.ng$Quality$
Risk$Based$Approaches$
!  57%(of(sponsors(and(58%(of(CROs(use(a(formal,(riskdbased(
approach(to(levels(of(site(monitoring((industry(survey(data)(
"  About(2/3(have(had(primarily(posi3ve(experiences(–(1/3(mixed(
!  Most(sponsors((67%)(and(CROs((79%)(do(maintain(
documenta3on(of(site(performance(on(previous(trials(to(
factors(into(such(models.(
"  Performance(data(most(commonly(includes(number(of(protocol(
viola3ons,(number(of(queries,(type(and(severity(of(protocol(
viola3ons,(promptness(of(data(entry,(types(of(queries,(and(3me(
to(resolu3on(of(queries.(
38(
Quality$by$Region$
39(
Summary$
!  While(developing(standards(and(more(
efficient(ways(for(sponsors(and(CROs(to(work(
together(is(necessary,(it(has(been(
challenging.(
!  There(is(greater(poten3al(for(success(in(
terms(of(the(ability(to(quickly(move(towards(
standards:(
( ( (Quality(Agreements(
( ( (Quality(Metrics(
!  There(is(no(onedsize(fits(all(CRO(model(
Open$Discussion$
(
Thank(You(

Contenu connexe

Similaire à A Peek at GCT 2012

2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docxeugeniadean34240
 
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Ankur Khanna
 
A Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare DesignA Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare DesignRichard Hogue
 
Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416Chirag Patel
 
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...Sean Ekins
 
Translational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discoveryTranslational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discoverypharmaindexing
 
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...Stockholm Institute of Transition Economics
 
Knowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call toolKnowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call toolChristine Wekerle
 
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
Running head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docxRunning head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docx
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docxhealdkathaleen
 
New Product Planning and Medical Affairs
New Product Planning and Medical AffairsNew Product Planning and Medical Affairs
New Product Planning and Medical AffairsAnthony Russell
 
Implicate order Probabilistic Semantics
Implicate order Probabilistic SemanticsImplicate order Probabilistic Semantics
Implicate order Probabilistic SemanticsSrinidhi Boray
 
The Drug Development Process Kerentech
The Drug Development Process KerentechThe Drug Development Process Kerentech
The Drug Development Process KerentechEstherMM
 
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...Joanne Sienko Ott, CFA, MA
 
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docxRoddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docxSUBHI7
 
Knowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text FinalKnowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text Finalkdjamies
 
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryMel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryJean-Claude Bradley
 

Similaire à A Peek at GCT 2012 (20)

2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
 
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
 
A Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare DesignA Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare Design
 
Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416
 
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
 
Translational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discoveryTranslational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discovery
 
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
 
Knowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call toolKnowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call tool
 
Searching for Relevant Studies
Searching for Relevant StudiesSearching for Relevant Studies
Searching for Relevant Studies
 
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
Running head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docxRunning head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docx
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
 
New Product Planning and Medical Affairs
New Product Planning and Medical AffairsNew Product Planning and Medical Affairs
New Product Planning and Medical Affairs
 
Implicate order Probabilistic Semantics
Implicate order Probabilistic SemanticsImplicate order Probabilistic Semantics
Implicate order Probabilistic Semantics
 
The Drug Development Process Kerentech
The Drug Development Process KerentechThe Drug Development Process Kerentech
The Drug Development Process Kerentech
 
When pharmaceutical companies publish large datasets an abundance of riches o...
When pharmaceutical companies publish large datasets an abundance of riches o...When pharmaceutical companies publish large datasets an abundance of riches o...
When pharmaceutical companies publish large datasets an abundance of riches o...
 
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
 
apcp Deeksha Bhartiya
apcp Deeksha  Bhartiyaapcp Deeksha  Bhartiya
apcp Deeksha Bhartiya
 
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docxRoddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
 
Literature Review on Health & Safety
Literature Review on Health & SafetyLiterature Review on Health & Safety
Literature Review on Health & Safety
 
Knowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text FinalKnowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text Final
 
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryMel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
 

Plus de ConferenceForum

Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsStrategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsConferenceForum
 
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkThomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkConferenceForum
 
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsGCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsConferenceForum
 
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...ConferenceForum
 
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerChanging Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerConferenceForum
 
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012ConferenceForum
 
Podd slide deck mark kontny
Podd slide deck   mark kontnyPodd slide deck   mark kontny
Podd slide deck mark kontnyConferenceForum
 
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1ConferenceForum
 
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012ConferenceForum
 

Plus de ConferenceForum (17)

A Peek at Dpharm 2012
A Peek at Dpharm 2012A Peek at Dpharm 2012
A Peek at Dpharm 2012
 
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsStrategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
 
Scott Harris
Scott HarrisScott Harris
Scott Harris
 
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkThomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
 
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsGCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging Markets
 
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
 
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerChanging Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz Stoner
 
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Podd slides 1
Podd slides 1Podd slides 1
Podd slides 1
 
Podd slides
Podd slidesPodd slides
Podd slides
 
Podd slide deck mark kontny
Podd slide deck   mark kontnyPodd slide deck   mark kontny
Podd slide deck mark kontny
 
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1
 
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012
 
Sohini Chowdhury, 2011
Sohini Chowdhury, 2011Sohini Chowdhury, 2011
Sohini Chowdhury, 2011
 

Dernier

How The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K SubscribersHow The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K SubscribersFlyyx Tech
 
14 march 2024-capital-markets-update eni.pdf
14 march 2024-capital-markets-update eni.pdf14 march 2024-capital-markets-update eni.pdf
14 march 2024-capital-markets-update eni.pdfEni
 
Benihana of Tokyo case study11111111.pdf
Benihana of Tokyo case study11111111.pdfBenihana of Tokyo case study11111111.pdf
Benihana of Tokyo case study11111111.pdfjavenxxx01
 
Strategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 UpdateStrategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 UpdateAdnet Communications
 
Unleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan BusinessUnleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan Businesstompeter3736
 
Shravan Kumaran and sanjay kumaran.pdf..
Shravan Kumaran and sanjay kumaran.pdf..Shravan Kumaran and sanjay kumaran.pdf..
Shravan Kumaran and sanjay kumaran.pdf..ranjithapriya2
 
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAYLouis Malaybalay
 
Record of Module Forensic photography in
Record of Module Forensic photography inRecord of Module Forensic photography in
Record of Module Forensic photography inalexademileighpacal
 
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptxA Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptxShainaMaheshwari1
 
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024believeminhh
 
A Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdfA Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdfmeftaul987
 
Mist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in EgyptMist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in Egyptopstechsanjanasingh
 
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities pptBus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities pptendeworku
 
EPC Contractors aspects Presentation.pdf
EPC Contractors  aspects Presentation.pdfEPC Contractors  aspects Presentation.pdf
EPC Contractors aspects Presentation.pdfGiuseppe Tommasone
 
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptxStreamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptxPaulBryant58
 
Digital Marketing Training Program skills s
Digital Marketing Training Program skills sDigital Marketing Training Program skills s
Digital Marketing Training Program skills sgodxzyrox
 
Wallet Pitch for startup fintech and loan
Wallet Pitch for startup fintech and loanWallet Pitch for startup fintech and loan
Wallet Pitch for startup fintech and loansujat8807
 
HOW TO START EARNING WITH AFFILIATE MARKETING
HOW TO START EARNING WITH AFFILIATE MARKETINGHOW TO START EARNING WITH AFFILIATE MARKETING
HOW TO START EARNING WITH AFFILIATE MARKETINGNATHAN SPEAKS
 
unfinished legacy it is a clothing brand
unfinished legacy it is a clothing brandunfinished legacy it is a clothing brand
unfinished legacy it is a clothing brandakashm530190
 

Dernier (20)

How The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K SubscribersHow The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K Subscribers
 
14 march 2024-capital-markets-update eni.pdf
14 march 2024-capital-markets-update eni.pdf14 march 2024-capital-markets-update eni.pdf
14 march 2024-capital-markets-update eni.pdf
 
Benihana of Tokyo case study11111111.pdf
Benihana of Tokyo case study11111111.pdfBenihana of Tokyo case study11111111.pdf
Benihana of Tokyo case study11111111.pdf
 
Strategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 UpdateStrategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 Update
 
Unleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan BusinessUnleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan Business
 
Shravan Kumaran and sanjay kumaran.pdf..
Shravan Kumaran and sanjay kumaran.pdf..Shravan Kumaran and sanjay kumaran.pdf..
Shravan Kumaran and sanjay kumaran.pdf..
 
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
 
Record of Module Forensic photography in
Record of Module Forensic photography inRecord of Module Forensic photography in
Record of Module Forensic photography in
 
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptxA Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
 
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
 
A Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdfA Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdf
 
Mist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in EgyptMist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in Egypt
 
WAM Corporate Presentation Mar 12 2024_Video.pdf
WAM Corporate Presentation Mar 12 2024_Video.pdfWAM Corporate Presentation Mar 12 2024_Video.pdf
WAM Corporate Presentation Mar 12 2024_Video.pdf
 
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities pptBus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
 
EPC Contractors aspects Presentation.pdf
EPC Contractors  aspects Presentation.pdfEPC Contractors  aspects Presentation.pdf
EPC Contractors aspects Presentation.pdf
 
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptxStreamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
 
Digital Marketing Training Program skills s
Digital Marketing Training Program skills sDigital Marketing Training Program skills s
Digital Marketing Training Program skills s
 
Wallet Pitch for startup fintech and loan
Wallet Pitch for startup fintech and loanWallet Pitch for startup fintech and loan
Wallet Pitch for startup fintech and loan
 
HOW TO START EARNING WITH AFFILIATE MARKETING
HOW TO START EARNING WITH AFFILIATE MARKETINGHOW TO START EARNING WITH AFFILIATE MARKETING
HOW TO START EARNING WITH AFFILIATE MARKETING
 
unfinished legacy it is a clothing brand
unfinished legacy it is a clothing brandunfinished legacy it is a clothing brand
unfinished legacy it is a clothing brand
 

A Peek at GCT 2012